Press Releases
ProBioGen’s GlymaxX® ADCC Enhancement Technology used by Betta Pharmaceuticals
read more ProBioGen’s GlymaxX® ADCC Enhancement Technology used by Betta Pharmaceuticals
ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks
read more ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks
ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform
read more ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform
ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program
read more ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program
ProBioGen and TEVA sign License Agreement on Human Artificial Lymph Node Technology
read more ProBioGen and TEVA sign License Agreement on Human Artificial Lymph Node Technology